|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GMFB |
Gene summary for GMFB |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GMFB | Gene ID | 2764 |
| Gene name | glia maturation factor beta | |
| Gene Alias | GMF | |
| Cytomap | 14q22.2 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | P60983 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2764 | GMFB | LZE4T | Human | Esophagus | ESCC | 1.09e-14 | 3.50e-01 | 0.0811 |
| 2764 | GMFB | LZE8T | Human | Esophagus | ESCC | 5.32e-04 | 7.66e-02 | 0.067 |
| 2764 | GMFB | LZE20T | Human | Esophagus | ESCC | 2.87e-03 | 9.40e-02 | 0.0662 |
| 2764 | GMFB | LZE24T | Human | Esophagus | ESCC | 1.15e-07 | 1.73e-01 | 0.0596 |
| 2764 | GMFB | P1T-E | Human | Esophagus | ESCC | 2.54e-03 | 1.21e-01 | 0.0875 |
| 2764 | GMFB | P2T-E | Human | Esophagus | ESCC | 1.31e-17 | 1.93e-01 | 0.1177 |
| 2764 | GMFB | P4T-E | Human | Esophagus | ESCC | 1.00e-22 | 5.89e-01 | 0.1323 |
| 2764 | GMFB | P5T-E | Human | Esophagus | ESCC | 6.54e-19 | 4.63e-01 | 0.1327 |
| 2764 | GMFB | P8T-E | Human | Esophagus | ESCC | 7.53e-21 | 4.12e-01 | 0.0889 |
| 2764 | GMFB | P9T-E | Human | Esophagus | ESCC | 6.15e-12 | 1.09e-01 | 0.1131 |
| 2764 | GMFB | P10T-E | Human | Esophagus | ESCC | 1.85e-34 | 6.50e-01 | 0.116 |
| 2764 | GMFB | P11T-E | Human | Esophagus | ESCC | 2.59e-08 | 5.80e-01 | 0.1426 |
| 2764 | GMFB | P12T-E | Human | Esophagus | ESCC | 1.87e-27 | 5.84e-01 | 0.1122 |
| 2764 | GMFB | P15T-E | Human | Esophagus | ESCC | 9.36e-48 | 1.14e+00 | 0.1149 |
| 2764 | GMFB | P16T-E | Human | Esophagus | ESCC | 4.15e-20 | 3.48e-01 | 0.1153 |
| 2764 | GMFB | P19T-E | Human | Esophagus | ESCC | 1.69e-02 | 5.41e-01 | 0.1662 |
| 2764 | GMFB | P20T-E | Human | Esophagus | ESCC | 8.80e-17 | 4.74e-01 | 0.1124 |
| 2764 | GMFB | P21T-E | Human | Esophagus | ESCC | 1.75e-23 | 5.42e-01 | 0.1617 |
| 2764 | GMFB | P22T-E | Human | Esophagus | ESCC | 9.74e-17 | 3.31e-01 | 0.1236 |
| 2764 | GMFB | P23T-E | Human | Esophagus | ESCC | 1.71e-07 | 2.69e-01 | 0.108 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003431415 | Esophagus | ESCC | Arp2/3 complex-mediated actin nucleation | 28/8552 | 39/18723 | 8.57e-04 | 4.40e-03 | 28 |
| GO:00343156 | Esophagus | ESCC | regulation of Arp2/3 complex-mediated actin nucleation | 16/8552 | 21/18723 | 4.47e-03 | 1.76e-02 | 16 |
| GO:00450108 | Esophagus | ESCC | actin nucleation | 33/8552 | 52/18723 | 7.38e-03 | 2.65e-02 | 33 |
| GO:004325412 | Liver | Cirrhotic | regulation of protein-containing complex assembly | 169/4634 | 428/18723 | 7.40e-12 | 4.99e-10 | 169 |
| GO:000701512 | Liver | Cirrhotic | actin filament organization | 171/4634 | 442/18723 | 3.93e-11 | 2.30e-09 | 171 |
| GO:190290312 | Liver | Cirrhotic | regulation of supramolecular fiber organization | 148/4634 | 383/18723 | 8.85e-10 | 4.08e-08 | 148 |
| GO:003297012 | Liver | Cirrhotic | regulation of actin filament-based process | 152/4634 | 397/18723 | 1.12e-09 | 5.00e-08 | 152 |
| GO:003295612 | Liver | Cirrhotic | regulation of actin cytoskeleton organization | 136/4634 | 358/18723 | 1.47e-08 | 5.49e-07 | 136 |
| GO:005125812 | Liver | Cirrhotic | protein polymerization | 116/4634 | 297/18723 | 2.87e-08 | 9.78e-07 | 116 |
| GO:011005312 | Liver | Cirrhotic | regulation of actin filament organization | 108/4634 | 278/18723 | 1.17e-07 | 3.32e-06 | 108 |
| GO:00313347 | Liver | Cirrhotic | positive regulation of protein-containing complex assembly | 95/4634 | 237/18723 | 1.21e-07 | 3.39e-06 | 95 |
| GO:190290512 | Liver | Cirrhotic | positive regulation of supramolecular fiber organization | 86/4634 | 209/18723 | 1.21e-07 | 3.39e-06 | 86 |
| GO:003227112 | Liver | Cirrhotic | regulation of protein polymerization | 92/4634 | 233/18723 | 4.25e-07 | 9.86e-06 | 92 |
| GO:000815412 | Liver | Cirrhotic | actin polymerization or depolymerization | 86/4634 | 218/18723 | 1.04e-06 | 2.13e-05 | 86 |
| GO:003004112 | Liver | Cirrhotic | actin filament polymerization | 77/4634 | 191/18723 | 1.41e-06 | 2.79e-05 | 77 |
| GO:003253512 | Liver | Cirrhotic | regulation of cellular component size | 135/4634 | 383/18723 | 2.32e-06 | 4.26e-05 | 135 |
| GO:005149512 | Liver | Cirrhotic | positive regulation of cytoskeleton organization | 87/4634 | 226/18723 | 2.96e-06 | 5.25e-05 | 87 |
| GO:00106397 | Liver | Cirrhotic | negative regulation of organelle organization | 124/4634 | 348/18723 | 3.20e-06 | 5.60e-05 | 124 |
| GO:003083312 | Liver | Cirrhotic | regulation of actin filament polymerization | 69/4634 | 172/18723 | 5.92e-06 | 9.65e-05 | 69 |
| GO:003227312 | Liver | Cirrhotic | positive regulation of protein polymerization | 58/4634 | 138/18723 | 5.96e-06 | 9.69e-05 | 58 |
| Page: 1 2 3 4 5 6 7 8 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GMFB | SNV | Missense_Mutation | novel | c.191N>A | p.Arg64Gln | p.R64Q | P60983 | protein_coding | tolerated(0.37) | benign(0.012) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| GMFB | SNV | Missense_Mutation | c.11N>A | p.Ser4Tyr | p.S4Y | P60983 | protein_coding | deleterious(0) | possibly_damaging(0.847) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| GMFB | SNV | Missense_Mutation | novel | c.239G>T | p.Gly80Val | p.G80V | P60983 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| GMFB | SNV | Missense_Mutation | c.199N>T | p.Arg67Cys | p.R67C | P60983 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| GMFB | SNV | Missense_Mutation | novel | c.359T>C | p.Val120Ala | p.V120A | P60983 | protein_coding | tolerated(0.06) | possibly_damaging(0.587) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| GMFB | SNV | Missense_Mutation | novel | c.166G>A | p.Glu56Lys | p.E56K | P60983 | protein_coding | deleterious(0.03) | benign(0.06) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| GMFB | SNV | Missense_Mutation | rs752098440 | c.121C>T | p.Arg41Cys | p.R41C | P60983 | protein_coding | deleterious(0) | possibly_damaging(0.695) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| GMFB | SNV | Missense_Mutation | novel | c.35N>G | p.Glu12Gly | p.E12G | P60983 | protein_coding | tolerated(0.09) | benign(0) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| GMFB | SNV | Missense_Mutation | rs752098440 | c.121N>T | p.Arg41Cys | p.R41C | P60983 | protein_coding | deleterious(0) | possibly_damaging(0.695) | TCGA-AJ-A8CT-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| GMFB | SNV | Missense_Mutation | rs771198764 | c.65N>A | p.Arg22His | p.R22H | P60983 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AP-A0LT-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |